HighTower Advisors
BEAM icon

HighTower Advisors’s Beam Therapeutics BEAM Stock Holding History

HighTower Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$240K Sell
10,088
-316
-3% -$8.77K ﹤0.01% 3350
2025
Q4 		$288K Sell
10,404
-32
-0.3% -$816 ﹤0.01% 3077
2025
Q3 		$253K Buy
+10,436
New +$208K ﹤0.01% 3183
2022
Q2 		– Sell
-4,352
Closed -$251K – 3253
2022
Q1 		$251K Buy
4,352
+576
+15% +$37.8K ﹤0.01% 2658
2021
Q4 		$301K Buy
+3,776
New +$323K ﹤0.01% 2469

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

HighTower Advisors's BEAM Position: Q1 2026 in Review

HighTower Advisors reduced its Beam Therapeutics (BEAM) stake by 3% in Q1 2026, selling an estimated $8.77K and leaving 10,088 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #3350.

HighTower Advisors first reported a position in BEAM in Q4 2021 and has held it in 5 quarters since. The position peaked at $301K in Q4 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • HighTower Advisors held 10,088 shares of Beam Therapeutics worth $240K as of Q1 2026.
  • HighTower Advisors sold 316 Beam Therapeutics shares in Q1 2026, an estimated $8.77K.
  • Beam Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3350 holding.
  • HighTower Advisors first reported a position in Beam Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • HighTower Advisors's Beam Therapeutics position peaked at $301K in Q4 2021.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.